Is cannabis Big Pharma’s latest drug?

With the medical marijuana market expected to hit US$ 40 billion by 2024, and the potential for cannabis compounds to displace opiates, traditional drugmakers are betting big on weed

Andrew Willis 14 March, 2019 | 5:00PM
Facebook Twitter LinkedIn

For much of 2018, cannabis has been in the spotlight. And so has Big Pharma. But what about Big Pharma in Cannabis? Are there - investable - medical miracles coming out of this combination of conventional and herbal medicine?

With the lead-up to legalization in Canada in October last year, the smell of profit was in the air as cannabis cultivator stocks soared and caught the attention of a variety of established industries – among them, pharmaceuticals.

“There’s more harmony here”, says Steeve Néron, Senior Vice President, Marketing & Medical Affairs at Tetra Bio-Pharma (TBP), a Canadian pharmaceutical company dedicated to cannabinoid-based drug discovery. The legality of cannabis in Canada creates clarity at a federal level not possible in the U.S., where individual states are separately leading legalization reforms.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free
Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar Rating
Canopy Growth Corp18.11 CAD4.56Rating
Novartis AG ADR82.80 USD-0.31Rating
Tetra Bio Pharma Inc0.26 CAD-1.92
Teva Pharmaceutical Industries Ltd ADR8.82 USD1.61Rating

About Author

Andrew Willis

Andrew Willis  is Content Editor for Follow him on Twitter @AndrewWillisCDN.


© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies